Xortx announces publication of key research in adpkd

Calgary, alberta, april 22, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “raising serum uric acid with a uricase inhibitor worsens pkd in rat and mouse models" has been accepted for publication in the peer-reviewed american journal of physiology-renal physiology and published online april 19, 2024.
XRTX Ratings Summary
XRTX Quant Ranking